| |
We are now working to investigate FGF-1 for many different applications, and have initiated pre-clinical testing for the following:
| · |
FGF-1 and Stroke – the goal of our pre-clinical research is to assess the effects of our drug candidate, CVBT-141F, in reducing brain damage due to stroke |
| · |
FGF-1 and Osteoporosis – to date we have seen positive pre-clinical results of the effects of our drug candidate, CVBT-141G, in an animal model of bone growth |
| · |
Lumbar Ischemia – the study is being conducted by Vance Gardner, M.D. and the Orthopaedic Education and Research Institute of Southern California |
Use of
this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics,
Inc.
All Rights Reserved.
Some content on this site requires the free Adobe
Reader.
| |